MAO-B inhibitors, hold the potential to be developed into effective anti-Alzheimer’s drugs, as it has been reported before, that MAO-B inhibitors such as selegiline and rasagiline has shown to significantly improve the learning and memory deficits in the animal models, associated with AD and to slow the disease progression in AD patients [11–13]. This evidence concerns the gene MAOB and Alzheimer disease.